(Reuters) – Eli Lilly expects sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street expectations in the fourth quarter, but forecast 2025 revenue largely above estimates.
The company said on Tuesday it expects $3.5 billion in Mounjaro sales in the fourth quarter, and $1.9 billion for Zepbound. Analysts had expected the drugs to bring in $5.35 billion and $2.08 billion, respectively, according to data compiled by LSEG.
“Our previous guidance had anticipated even faster acceleration of growth for the quarter. That, in addition to lower-than-expected channel inventory at year-end, contributed to our Q4 results,” CEO David Ricks said.
Lilly said it expects 2025 sales between $58 billion and $61 billion. Analysts were expecting revenue of $58.52 billion.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Shounak Dasgupta)
Comments